In particular, the lost LC is exclusively the modified one that contains the TCR constant domain (Fig. While purifying a symmetric WuXiBody-based bsAb, we identified a LC-missing species as a major byproduct. BsAbs based on WuXiBody can adopt either asymmetric or symmetric format. WuXiBody's sequence replacement has a similar effect as domain crossover in the CrossMab approach. Its key feature is the replacement of one parental antibody's CH1/CL region with the T cell receptor (TCR) constant domain, which promotes cognate heavy chain (HC)-light chain (LC) pairing. This platform enables any monoclonal antibody sequence pair to be assembled into a bispecific construct.
WuXiBody is a bispecific antibody (bsAb) platform developed by WuXi Biologics.
In this study, we demonstrated that when Capto MMC ImpRes chromatography is conducted under weak partitioning mode, high throughput, good yield, and effective byproduct removal are simultaneously achieved. However, the dynamic binding capacity (DBC) of Capto MMC ImpRes is relatively low under the selected condition, making the process less desirable for large-scale manufacturing. We previously showed that Capto MMC ImpRes mixed-mode chromatography under bind-elute mode can effectively remove this LC-missing species. While for bsAbs based on other platforms removal of such byproduct can pose considerable challenge to the downstream team, in this case WuXiBody's unique design makes separation relatively straightforward. For purifying a WuXiBody-based symmetric bsAb, we identified a LC-missing species as a major byproduct. Its key feature is the replacement of one parental antibody's CH1/CL region with the T cell receptor (TCR) constant domain, a design that promotes cognate heavy chain (HC)-light chain (LC) pairing.
0 kommentar(er)
